Ferrograd Folic 325/0.35mg Prolonged Release Tablets 30 Pack

Directions:

• Adults: The recommended dosage is one tablet daily before food.
• Children: Not applicable.
• Elderly: As for adults.

The sustained release tablet and its inert plastic matrix may

cause a safety hazard in some elderly or other patients suffering from delayed intestinal transit.

The tablets should not be sucked, chewed or kept in the mouth, but swallowed whole with water. Tablets should be taken before meals or during meals, depending on gastrointestinal tolerance.

*  Medical advice should be sought if symptoms do not improve after four weeks of use of this product as these symptoms may reflect on underlying disease process.

HAZARDS & CAUTIONS

• Contains iron. Keep out of reach and sight of children, as overdose may be fatal.
• Caution is advised in individuals with a family history of haemochromatosis or iron overload syndromes. It should be noted these conditions may be under diagnosed. Overdose may be fatal. As with all iron preparations, this product should be used with caution in patients with haemochromatosis, haemolytic anaemia or haemoglobinopathies.
• The sustained release tablet and its inert plastic matrix may cause a safety hazard in patients suffering from delayed intestinal transit. There may also be a further delay in release of the iron.
• Ferrograd Folic contains the colour E124, which may cause allergic type reactions including asthma. Allergy is more common in those people who are allergic to aspirin.
• Due to the risk of mouth ulcerations and tooth discolouration, tablets should not be sucked, chewed or kept in the mouth, but swallowed whole with water.
• Aspiration of iron sulphate tablets can cause necrosis of the bronchial mucosa which may result in coughing, haemoptysis, broncho stenosis and/or pulmonary infection (even if aspiration happened days to months before these symptoms occurred).
• Elderly patients and patients who have difficulties swallowing should only be treated with iron sulphate tablets after a careful evaluation of the individual patient's risk of aspiration.
• Alternative formulations should be considered. Patients should seek medical attention in case of suspected aspiration.

TABLET CORE:

Methylacrylate methylmethacrylate copolymer

Magnesium stearate

Macrogol 8000

Dye red ponceau 4R lake (E124)

Titanium dioxide (E171)

Colloidal Anhydrous Silica

Povidone

Sucrose (Sugar)

Lactose Monohydrate

Acacia powder

Maize starch

FILM COATING:

Cellacefate

Macrogol 8000

Propylene glycol

Sorbitan Oleate

Castor oil, virgin